0000899243-22-016538.txt : 20220504 0000899243-22-016538.hdr.sgml : 20220504 20220504090258 ACCESSION NUMBER: 0000899243-22-016538 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220504 FILED AS OF DATE: 20220504 DATE AS OF CHANGE: 20220504 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gollob Jared CENTRAL INDEX KEY: 0001821198 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39460 FILM NUMBER: 22889983 MAIL ADDRESS: STREET 1: C/O KYMERA THERAPEUTICS, INC. STREET 2: 200 ARSENAL YARDS, SUITE 230 CITY: WATERTOWN STATE: MA ZIP: 02472 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kymera Therapeutics, Inc. CENTRAL INDEX KEY: 0001815442 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 812992166 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 ARSENAL YARDS BLVD., SUITE 230 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 857-285-5314 MAIL ADDRESS: STREET 1: 200 ARSENAL YARDS BLVD., SUITE 230 CITY: WATERTOWN STATE: MA ZIP: 02472 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-05-04 0 0001815442 Kymera Therapeutics, Inc. KYMR 0001821198 Gollob Jared C/O KYMERA THERAPEUTICS, INC. 200 ARSENAL YARDS BLVD., SUITE 230 WATERTOWN MA 02472 0 1 0 0 Chief Medical Officer Common Stock 2022-05-04 4 M 0 10208 1.31 A 47465 D Common Stock 2022-05-04 4 M 0 9792 2.08 A 57257 D Stock Option (Right to Buy) 1.31 2022-05-04 4 M 0 10208 0.00 D 2028-10-31 Common Stock 10208 29799 D Stock Option (Right to Buy) 2.08 2022-05-04 4 M 0 9792 0.00 D 2029-05-22 Common Stock 9792 109020 D Twenty-five percent (25%) of the shares underlying this stock option vested on September 12, 2019 and the remaining shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date. /s/ Bruce N. Jacobs, as Attorney-in-Fact 2022-05-04